KIT and breast carcinoma: CD117 was expressed in about 40% of the basal-like carcinomas, in around 13% of HER2 amplified carcinomas and in 5% of luminal carcinomas making this marker of limited or no value in segregating neuroendocrine subtypes of breast carcinoma.